Canagliflozin (CANA), a new class of antidiabetic agents, can inhibit AKT/mTOR pathways, leading to the blockage of HIF-1α synthesis, thereby suppressing glycolysis, metastasis, angiogenesis, and EMT in HCC (160). Here, AKT1 is linked to hepatocellular carcinoma.